Drug-eluting stents - Emerging trends
A few years after their introduction in 2002, drug-eluting stents had all but replaced bare-metal stents in the treatment of coronary heart disease, capturing up to 90% of the market. PMost of the pysicians favored the new stents primarily because of their ability to minimize the risk of restenosis associated with bare-metal stents.
Recently, however, new safety concerns have begun to erode the market share of drug-eluting stents.
Recently, however, new safety concerns have begun to erode the market share of drug-eluting stents.
Comments